Abstracts tagged "Osteoarthritis"

Abstract Number: 1979 • 2019 ACR/ARP Annual Meeting
What Is the Pathogenic Meaning of Chondrocyte Hypertrophy in Osteoarthritis? Effect of Evc Deletion Through Hedgehog Signaling
Ana Lamuedra¹, Paula Gratal ¹, Víctor Luis Ruiz-Perez ², Adrián Palencia-Campos ³, Sergio Portal-Nuñez ⁴, Gabriel Herrero-Beaumont ⁵ and Raquel Largo ⁵, ¹IIS - Fundacion Jimenez Diaz, Madrid, Madrid, Spain, ²Instituto de Investigaciones Biomédicas 'Alberto Sols', Madrid, Madrid, Spain, ³Adrián Palencia Campos [[email protected]], Madrid, Madrid, Spain, ⁴Applied Molecular Medicine Institute (IMMA), Universidad San Pablo-CEU, Alcorcón, Madrid, Spain, ⁵IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain
Background/Purpose: Osteoarthritis (OA) is mainly characterized by the progressive damage of articular cartilage, where chondrocytes acquire a hypertrophic-like phenotype. Indian Hedgehog levels are increased in…
Abstract Number: 2178 • 2019 ACR/ARP Annual Meeting
Associations Between Baseline and Longitudinal Quantitative Joint Space Width and Incident Hip Osteoarthritis: The Johnston County Osteoarthritis Project
Jacquelyn Smith¹, Carolina Alvarez ¹, Liubov Arbeeva ¹, Jordan Renner ², Louise Murphy ³, Joanne Jordan ¹, Yvonne Golightly ⁴, Jeffrey Duryea ⁵ and Amanda Nelson ¹, ¹University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Chapel Hill, NC, ²University of North Carolina at Chapel Hill Department of Radiology, Chapel Hill, NC, ³Centers for Disease Control and Prevention, Division of Population Health, Atlanta, ⁴University of North Carolina at Chapel Hill Department of Epidemiology and Thurston Arthritis Research Center, Chapel Hill, NC, ⁵Harvard Medical School Department of Radiology Brigham and Women's Hospital, Boston, MA
Background/Purpose: To quantify associations between baseline and change in computer-assisted hip quantitative joint space width (qJSW) with incident radiographic (rHOA) or symptomatic (sxHOA) hip OA.Methods:…
Abstract Number: 2203 • 2019 ACR/ARP Annual Meeting
Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study
Jacek Kopec¹, Eric Sayre ², Anya Okhmatovskaia ³, Jolanda Cibere ⁴, Linda Li ⁵, Nick Bansback ⁶, Hubert Wong ⁵ and John Esdaile ⁷, ¹Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Vancouver, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of British Columbia, Vancouver, Canada, ⁷Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada
Background/Purpose: Analgesics are the cornerstone of medical treatment of osteoarthritis (OA) but are associated with serious side effects. A more optimal use of analgesics in…
Abstract Number: 821 • 2019 ACR/ARP Annual Meeting
Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD)
Subhashisa Swain¹, Aliya Sarmanova ², Christian Mallen ³, Chang Fu Kuo ⁴, Carol Coupland ⁵ and Weiya Zhang ⁶, ¹University of Nottingham, Nottingham, England, United Kingdom, ²2. Bristol Medical School, Population Health Sciences, University of Bristol, UK, Bristol, England, United Kingdom, ³Research Institute for Primary Care and Health Sciences, Keele University, UK, Keele, United Kingdom, ⁴4. Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan (Republic of China), ⁵5. Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, England, United Kingdom, ⁶1. Academic Rheumatology, Division of Rheumatology, Orthopaedics and Dermatology, University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Osteoarthritis (OA) is by far the most common arthritis.(1) However, its chronological trend in the United Kingdom (UK) is not known. We aimed to…
Abstract Number: 1307 • 2019 ACR/ARP Annual Meeting
A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain
Antonia Chen¹, Fred Khalouf ², Michael DePalma ³, Keith Zora ⁴, Lynn Kohan ⁵, Maged Guirguis ⁶, Douglas Beall ⁷, Eric Loudermilk ⁸, Matthew Pingree ⁹, Ignacio Badiola ¹⁰ and Jeffrey Lyman ¹¹, ¹Brigham and Women’s Hospital, Boston, MA, ²University Orthopedics Center, Altoona, PA, ³Virginia iSpine Physicians, Richmond, VA, ⁴University Orthopedics Center, State College, PA, ⁵University of Virginia School of Medicine, Charlottesville, VA, ⁶Ochsner Clinic Foundation, New Orleans, LA, ⁷Clinical Investigations, Edmond, OK, ⁸PCPMG Clinical Research Unit LLC, Anderson, SC, ⁹Mayo Clinic, Rochester, MN, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Institute for Orthopedic Research and Innovation, Coeur d'Alene, IN
Background/Purpose: This prospective, randomized, multi-center study was conducted to compare pain relief, functional improvement, and the safety of cooled radiofrequency ablation (CRFA) to hyaluronic acid…
Abstract Number: 1326 • 2019 ACR/ARP Annual Meeting
Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Ismail Simsek ¹, Chris Swearingen ¹, Sarah Kennedy ¹, Jeyanesh Tambiah ¹, Yusuf Yazici², Nancy Lane ³ and Marc C. Hochberg ⁴, ¹Samumed, LLC, San Diego, ²Samumed, LLC, San Diego, CA, ³University of California at Davis Medical Center, Sacramento, CA, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Recent concerns over osteoarthritis (OA) pharmacotherapy safety have led to revision of treatment guidelines and highlight the need for therapies with good safety profiles.…
Abstract Number: 1980 • 2019 ACR/ARP Annual Meeting
Disorganization of Chondrocyte Columns in the Growth Plate During Experimental Osteoarthritis in Mice
Ana Lamuedra¹, Víctor Luis Ruiz-Perez ², Paula Gratal ¹, Raquel Largo ³ and Gabriel Herrero-Beaumont ³, ¹IIS - Fundacion Jimenez Diaz, Madrid, Madrid, Spain, ²Instituto de Investigaciones Biomédicas 'Alberto Sols', Madrid, Madrid, Spain, ³IIS-Fundación Jiménez Díaz, Madrid, Madrid, Spain
Background/Purpose: Osteoarthritis (OA) is a biomechanical joint disease mainly affecting articular cartilage and subchondral bone. A great variety of animal models, especially mice, are used…
Abstract Number: 2179 • 2019 ACR/ARP Annual Meeting
Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort
Natividad Oreiro¹, Ignacio Rego-Pérez ¹, Maria T. Silva ¹, Sara Relaño ¹, Mercedes Fernandez-Moreno ², Paula Ramos-Louro ¹, Alejandro Duran-Sotuela ¹, Sonia Pertega ³ and Francisco J. Blanco ¹, ¹Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ²Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España. CIBER-BBM, A Coruña, Spain, ³Unidad de Epidemiología Clínica y Bioestadística. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Erosive hand osteoarthritis (EOA) is often considered a more severe form of hand OA. However, more data are needed regarding this phenotype to conclude…
Abstract Number: 2220 • 2019 ACR/ARP Annual Meeting
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
Nancy Lane¹, Richard Weiss ², Bruce Mitlak ³, Yamei Wang ⁴, Guillermo Valenzuela ⁵ and Chad Deal ⁶, ¹University of California at Davis Medical Center, Sacramento, CA, ²Radius Health, Inc, Waltham, ³Radius Health, Inc, Waltham, MA, ⁴Radius Health, Inc, Waltham, ⁵Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁶Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Osteoporosis (OP) and osteoarthritis (OA) are often comorbid conditions in the elderly, with prevalence of OP in patients with OA reported as high as…
Abstract Number: 875 • 2019 ACR/ARP Annual Meeting
Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial
Tim Pelle¹, Karen Bevers ¹, Job van der Palen ², Frank van den Hoogen ³ and Cornelia van den Ende ¹, ¹Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, ²Department of research methodology, Univeristy of Twente, Enschede, Netherlands, ³Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Self-management is of paramount importance in non-surgical treatment of knee/hip osteoarthritis (OA). Modern technologies offer the possibility to support self-management 24/7. We developed an…
Abstract Number: 1308 • 2019 ACR/ARP Annual Meeting
Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Sarah Kennedy ¹, Chris Swearingen ¹, Jeyanesh Tambiah¹, Daniel Clauw ² and Philip G Conaghan ³, ¹Samumed, LLC, San Diego, ²Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Patient-reported outcomes (PROs) in knee osteoarthritis (OA) trials have been difficult to accurately measure due to heterogenous sources of pain (e.g., from comorbid conditions…
Abstract Number: 1327 • 2019 ACR/ARP Annual Meeting
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Yusuf Yazici¹, Sarah Kennedy ², Chris Swearingen ² and Jeyanesh Tambiah ², ¹Samumed, LLC, San Diego, CA, ²Samumed, LLC, San Diego
Background/Purpose: Lorecivivint (LOR, SM04690) is a small-molecule, intra-articular (IA) CLK/DYRK1A inhibitor which modulates the Wnt pathway and has demonstrated beneficial effects on patient-reported outcomes (PROs)…
Abstract Number: 1982 • 2019 ACR/ARP Annual Meeting
Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain
Christopher Yohn ¹, Robert O'Brien ¹, Stephanie Lussier ¹, Casey Berridge ¹, Rathi Ryan ¹, Ali Guermazi ², Mahru An ¹, Remi-Martin Laberge ¹, Benjamin Hsu¹, Carl Millward ¹, Kate Doherty ¹ and Jamie Dananberg ¹, ¹Unity Biotechnology, Brisbane, CA, ²Boston Medical Center, Boston
Background/Purpose: Background/Purpose: Cellular senescence is a natural state in which a cell permanently halts division through upregulation of a set of intracellular proteins including p16INK4A…
Abstract Number: 2181 • 2019 ACR/ARP Annual Meeting
Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study
Lisa Pardaens ¹, Tine Vanhaverbeke ¹, Jordy Vandercruyssen ¹ and Ruth Wittoek², ¹Ghent University, Gent, Belgium, ²Ghent University Hospital, Gent University, Gent, Belgium
Background/Purpose: Limited evidence is available about natural disease progression in hand osteoarthritis (HOA). A previous study of the Ghent HOA cohort showed a positive association…
Abstract Number: 2244 • 2019 ACR/ARP Annual Meeting
What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?
Thomas Schnitzer¹, Rebecca Robinson ², Lars Viktrup ², Joseph Cappelleri ³, Andrew Bushmakin ³, Leslie Tive ⁴, Jennifer Mellor ⁵, Nathan Williams ⁵, Pavlina Hubanova ⁵ and James Jackson ⁵, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Eli Lilly and Company, Indianapolis, IN, ³Pfizer Inc, Groton, CT, ⁴Pfizer, Inc, New york, NY, ⁵Adelphi Real World, Bollington, England, United Kingdom
Background/Purpose: To describe patterns of care and physician satisfaction with prescribed treatments for osteoarthritis (OA).Methods: Data were collected from February-May 2017 using US Adelphi Disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.